Trials / Withdrawn
WithdrawnNCT03596970
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
A 24-month Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Evolution of Renal Function in Maintenance Liver Transplant Recipients Receiving Either RAD001 (Everolimus) Plus Reduced TAC or RAD001 (Everolimus) Plus Mycophenolate Mofetil (MMF)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A 24-month multi-center, open-label, randomized, controlled study to evaluate the evolution of renal function in maintenance liver transplant recipients receiving everolimus plus reduced TAC or everolimus plus mycophenolate mofetil (MMF)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAC withdrawal | Everolimus (RAD001) with MMF and Steroids |
| DRUG | Everolimus with reduced TAC | Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids |
Timeline
- Start date
- 2015-09-01
- Primary completion
- 2020-12-01
- Completion
- 2020-12-01
- First posted
- 2018-07-24
- Last updated
- 2018-07-24
Source: ClinicalTrials.gov record NCT03596970. Inclusion in this directory is not an endorsement.